Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX)

Price 0.05p on 02-01-2025 at 16:40:58
Change 0.0025p 5.26%
Buy 0.055p
Sell 0.045p
Buy / Sell NFX Shares
Last Trade: Sell 1,000,000.00 at 0.0499p
Day's Volume: 5,831,986
Last Close: 0.05p
Open: 0.045p
ISIN: GB00BYW79Y38
Day's Range 0.045p - 0.05p
52wk Range: 0.04p - 0.44p
Market Capitalisation: £710k
VWAP: 0.049171p
Shares in Issue: 1,419m

Recent Trades History Nuformix (NFX)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,000,000 0.0499p Ordinary
16:18:50 - 02-Jan-25
Sell* 131 0.04667p Ordinary
14:19:33 - 02-Jan-25
Buy* 1,500,000 0.05p Automatic Execution
10:31:06 - 02-Jan-25
Sell* 150 0.045p SI Trade
10:15:22 - 02-Jan-25
Buy* 2,026,741 0.0488p Ordinary
10:15:21 - 02-Jan-25
Buy* 1,206,432 0.0485p Ordinary
09:39:54 - 02-Jan-25
Unknown* 49,266 0.045p OTC Trade
09:22:17 - 02-Jan-25
Sell* 49,266 0.045p Automatic Execution
09:22:17 - 02-Jan-25

Share Price History for Nuformix

Time period:
to
Date Open High Low Close Volume

Share News for Nuformix

UK shareholder meetings calendar - next 7 days

28th Oct 2024 12:27

Read More

IN BRIEF: Nuformix shares fall despite interim loss narrowing

18th Jun 2024 18:37

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Posts no revenue in the six months ended March 31, unchanged from a year earlier. Pretax loss narrows to GBP242,529 from GBP337,622. Read More

Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment

17th Jun 2024 10:37

(Alliance News) - Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further protections for its fibrosis and oncology technology. Read More

UK shareholder meetings calendar - next 7 days

12th Mar 2024 14:30

Read More

IN BRIEF: Nuformix announces subscription to raise GBP150,000

1st Mar 2024 10:31

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis. Read More

FTSE 100 Latest
Value8,260.09
Change87.07

Login to your account

Forgot Password?

Not Registered